BGX Sofix Ucits Etf

RNS Number:4860G
Bioganix PLC
29 October 2007

Bioganix PLC ("Bioganix", the Company") is pleased to announce the appointments
of Oliver John Collinson O'Toole (46) and Professor Jeremy Myles Tavare (46) as
executive (Operations Director) and non-executive directors of the Company
respectively.



Oliver O'Toole (previously Oliver Toole) has worked for Bioganix since January
2006 as the Company's Technical and Operations manager.  Oliver graduated from
Oxford University in 1983 with a degree in Engineering, Economics and
Management.  Prior to joining Bioganix, Oliver held a number of senior positions
in engineering, manufacturing and consultancy businesses.  Since joining
Bioganix, Oliver has made a major contribution to the growth and development of
the business, in particular the establishment of the Suffolk (Parham) operation.
The Directors of Bioganix are delighted to welcome Oliver to the Board and
look forward to his on-going contribution to the development of Bioganix.



Professor Jeremy Tavare is the Professor of Biochemistry at the University of
Bristol.  He is also a director of ProXara Biotechnology Limited.  Jeremy
graduated from Bristol University in 1982 and was awarded a PhD by the same in
1986.  Since then he has pursued an academic career at the University of Bristol
with a one year Fellowship at the Howard Hughes Medical Institute in the USA.
Through his work with ProXara (a biotechnology company) and committee work
within Bristol University and at the Medical Research Council, Jeremy has
amassed significant board and commercial experience.  Bioganix are looking
forward to Jeremy's contribution to both the scientific and commercial aspects
of the business.


The following is disclosed in accordance with Schedule 2 paragraph (g) of the 
AIM Rules:

Oliver O'Toole:

Directorships in the last 5 years:

*         TWMPA Technology Limited (current - dormant, in process of 652a 
          application for striking off)
*         TWMPA Solutions Limited (current)

Jeremy Tavare:

Directorships in the last 5 years:


*         ProXara Biotechnology Limited (current)

*         MonoMed Limited (current)



There are no further matters to disclose in accordance with Schedule 2 paragraph
(g) of the AIM Rules.

Enquiries:


Nick Helme, Managing Director, Bioganix plc                    Tel:  01568 619 115
Julian Morgan, Finance Director, Bioganix plc                  Tel:  01568 619 101

Mike Coe, Blue Oar Securities Plc                              Tel:  0117 933 0020
Paul Vann/Tom Cooper, Winningtons Financial PR                 Tel:  0117 920 0092




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAMFBFTMMATBLR

Sofix Ucits Etf (LSE:BGX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Sofix Ucits Etf (LSE:BGX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024